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Interaction of Mesoporous Silica Nanoparticles with Human Red Blood
Cell Membranes: Size and Surface Effects
Abstract
The interactions of mesoporous silica nanoparticles (MSNs) of different particle sizes and surface properties
with human red blood cell (RBC) membranes were investigated by membrane filtration, flow cytometry, and
various microscopic techniques. Small MCM-41-type MSNs (∼100 nm) were found to adsorb to the surface
of RBCs without disturbing the membrane or morphology. In contrast, adsorption of large SBA-15-type
MSNs (∼600 nm) to RBCs induced a strong local membrane deformation leading to spiculation of RBCs,
internalization of the particles, and eventual hemolysis. In addition, the relationship between the degree of
MSN surface functionalization and the degree of its interaction with RBC, as well as the effect of RBC−MSN
interaction on cellular deformability, were investigated. The results presented here provide a better
understanding of the mechanisms of RBC−MSN interaction and the hemolytic activity of MSNs and will
assist in the rational design of hemocompatible MSNs for intravenous drug delivery and in vivo imaging.
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R
ecent advancements in particle size
and morphology control of mesopor-
ous materials have led to the creation
of nano- and submicrometer-sized meso-
porous silica nanoparticles (MSNs).1-5 The
MSN materials with well-ordered cylindrical
pore structures, such as MCM-41 and SBA-15,
have attracted special interest in the biomedi-
cal ﬁeld.1 The large surface areas and pore
volumes of these materials allow the eﬃ-
cient adsorption of a wide range of molec-
ules, including small drugs,6-10 therapeutic
proteins,11-13 antibiotics,14,15 and antibodies.16
Therefore, thesematerials have been proposed
foruseaspotentialvehicles forbiomedical imag-
ing, real-time diagnosis, and controlled deliv-
ery of multiple therapeutic agents.6-8,10,17-25
Despite the considerable interest in the
biomedical applications of MSNs, relatively
few studies have been published on the
biocompatibility of the two most common
types of MSNs (MCM-41 and SBA-15).26-29
Asefa and co-workers reported that the
cellular bioenergetics (cellular respiration
and ATP levels) were inhibited remarkably
by large SBA-15 nanoparticles, but the inhi-
bition was greatly reduced by smaller MCM-
41-type nanoparticles.26 These diﬀerences
in the disruption of cellular bioenergetics
are believed to be caused by the diﬀerent
surface areas, number of surface silanol
groups, and/or particle sizes of both types
of material. A recent study by Kohane and
collaborators on the systemic eﬀects of MCM-
41 (particle size ∼150 nm) and SBA-15
(particle size ∼800 nm) MSNs in live animals
revealed interesting ﬁndings regarding their
biocompatibility.27While large doses ofmeso-
porous silicas administered subcutaneously
to mice appear to be relatively harmless,
the same doses given intravenously or intra-
peritoneally were lethal.27 A possible reason
for the severe systemic toxicity of MSNs
when injected intravenously could be the
interactions of the nanoparticles with blood
cells.
Our initial studies on the biocompatibility
of MCM-41-type MSNs with red blood cells
(RBCs), the dominant (99%) cell type in blood,
suggested that this material was innocuous
in comparison to the highly hemolytic
amorphous silica.30 These results were later
conﬁrmed by Lin and Haynes, who demon-
strated that the hemocompatibility of
MSNs also depended on the size of the
nanoparticles.31 These ﬁndings weremainly
based on hemolysis assays performed by
UV-vis spectroscopy. The lack of hemolysis,
however, does not necessarily warrant the
absence of interactions between the parti-
cles and the RBCs, which could lead to more
subtle side eﬀects. Such side eﬀects could
eventually be the ones responsible for the
enhanced systemic toxicity observed upon
intravenous injection of these materials.27
Therefore, an in-depth study of other pos-
sible biological side eﬀects of these materi-
als must be performed if they are intended
to be applied as vehicles for drug delivery.
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ABSTRACT The interactions of mesoporous silica nanoparticles (MSNs) of diﬀerent particle
sizes and surface properties with human red blood cell (RBC) membranes were investigated by
membrane ﬁltration, ﬂow cytometry, and various microscopic techniques. Small MCM-41-type
MSNs (∼100 nm) were found to adsorb to the surface of RBCs without disturbing the membrane
or morphology. In contrast, adsorption of large SBA-15-type MSNs (∼600 nm) to RBCs induced a
strong local membrane deformation leading to spiculation of RBCs, internalization of the
particles, and eventual hemolysis. In addition, the relationship between the degree of MSN
surface functionalization and the degree of its interaction with RBC, as well as the eﬀect of
RBC-MSN interaction on cellular deformability, were investigated. The results presented here
provide a better understanding of the mechanisms of RBC-MSN interaction and the hemolytic
activity of MSNs and will assist in the rational design of hemocompatible MSNs for intravenous
drug delivery and in vivo imaging.
KEYWORDS: mesoporous silica nanoparticle (MSN) . size . surface functionality .
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In general, our knowledge of the biocompatibility,
bioretention, and biodistribution of MSNs does not
match with the rapid pace of research on their synthe-
ses in numerous forms and structures. To date, eﬀorts
have focused predominantly on exploiting multifunc-
tional nanoparticles as intravascular drug carriers with
diﬀerent particle sizes ranging from a few tens of
nanometers4,24,32 up to hundreds of nanometers,3,5
various pore diameters ranging from 2 to 10 nm,5,11,33
and assorted surface functionalities from small organic
groups (e.g., amino,34,35 carboxyl,35 thiol,35phosphate,19etc.)
to large molecules (e.g., dendrimers,36 polyethyleneimine
(PEI),25,37 poly(ethylene glycol) (PEG),38 phospholipids,39
etc.). Unfortunately, these endeavors are limited by a
poor understanding of particle interactions with cells in
circulation.
Herein, we report our investigations on the inter-
actions of the twomost common types ofMSNs (MCM-41
and SBA-15) with RBC membranes using ﬂuorescence
and electronmicroscopies and cell biology techniques.
In addition to studying the eﬀects of particle size and
surface area on the hemolytic behavior of MSNs, we
explored the eﬀects that the chemical nature and
degree of surface functionalization of the particles
have on their interactions with RBCs. Understanding
these eﬀects will not only oﬀer a guide for the rational
design of biocompatible particles but also provide an
insight into how to control the circulation properties of
MSNs in the bloodstream. In fact, a prolonged circula-
tion of polymeric nanoparticles has been recently
demonstrated by means of their noncovalent attach-
ment to the RBC membrane.40 Attachment to the RBC
membrane, however, may aﬀect one of its most im-
portant properties, namely, its deformability (i.e., the
ability of an erythrocyte to deform so it can ﬂow
through microcirculation). To the best of our knowl-
edge, this problem has not yet been addressed for any
drug delivery system. In this work, we examined the
eﬀect of RBC-MSN interactions onmembrane deform-
ability by the Nucleopore ﬁltration technique41 and
established how size and surface properties can alter
this important property. Overall, we propose three
fundamental criteria to assess the hemocompatibility
of nanoparticles: (1) hemolytic potential, (2) propensity
to induce RBC membrane deformation or morpholo-
gical alteration, and (3) tendency to impair RBC de-
formability. The evaluation of these conditions will
enable a more adequate estimation of the hemocom-
patibility of many types of nanomaterials. This study
suggests a minimal set of criteria that must be met
before performing in vivo studies involving the intra-
vascular administration of nanoparticles.
RESULTS AND DISCUSSION
Size- and Surface-Dependent MSN Interaction with RBC
Membranes. While particle size effect of MCM-41-type
MSNs has already been established with larger particles
producing lower hemolysis on RBC,31 the question
remainswhether the typically larger SBA-15-typeMSNs
are hemocompatible. A more critical issue is that the
mechanism of how MSNs of different sizes and surface
areas correlate and contribute to their hemocompat-
ibility is unclear, although several biological rationales
have been suggested.30,31 To address these questions,
we prepared two types of MSNs: MCM-41 and SBA-15,
as described in theMethods section. Scanning electron
microscopy (SEM) and transmission electron micro-
scopy (TEM) images showed particle sizes of 100 to
200 nm for the MCM-41-type MSNs (referred to as
s-MSN, Figure 1a,d) and ∼600 nm by ∼300 nm for the
SBA-15-type MSNs (referred as l-MSN, Figure 1b,e). The
hydrodynamic particle size distributions of the materi-
als suspended in phosphate-buffered saline (PBS)
(100 μgmL-1) were determined by dynamic light scatter-
ing (DLS), giving average sizes of 122 nm for s-MSN and
531 nm for l-MSN (Figure 1c). XRD patterns showed that
both s-MSNs and l-MSNs exhibit 2D hexagonal pore
arrangements (Figure 1f).
The hemolysis assay was used to evaluate the
hemolytic behaviors of s-MSN and l-MSN on human
RBCs. Human RBCs were ﬁrst isolated by centrifugation
and puriﬁed by ﬁve successive washes with sterile
isotonic PBS, then diluted to 5% hematocrit with PBS
before incubating with MSN suspensions of various
concentrations. Controls were prepared in the same
manner as the above RBC samples except adding
water (positive control) and PBS (negative control)
instead of the MSN suspensions. After a 2 h incubation
at room temperature, the samples were spun down for
the detection of hemoglobin released from hemolyzed
RBCs. Surprisingly, contrary to the recently reported
trend regarding size,31 MSNs with larger particle size
exhibited a higher hemolytic activity than the small
particles (Figure 2). The hemolytic activity of l-MSNs
was ﬁrst observed at 50 μg mL-1 with 5% hemolysis
detected, while a good hemocompatibility (<2%
hemolysis) of s-MSN was conﬁrmed at concentrations
as high as 100 μg mL-1. While a larger particle size
may be preferable for hemocompatible MSNs below
225 nm,31 increasing particle size of MSNs beyond this
range will not necessarily improve the hemocompat-
ibility as one might intuitively expect. In addition to
particle size, other factors such as the surface area are
also expected to aﬀect the hemolytic potential of MSNs.
To elucidate the mechanism of the observed diﬀer-
ence in hemolysis and investigate the underlying particle
size and surface eﬀects, the interaction ofMSNswith RBCs
were visualized by SEM (Figure 3) and TEM (Figure 4). A
small proportion of s-MSNs were found to adsorb to the
surface of RBC. The cell membrane did not show any
alteration upon particle binding, and RBCs maintained
normal biconcave shape compared to control RBCs
(Figure3BandFigure4 top). In contrast, a largeproportion
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strong local membrane deformation, which frequently
resulted in particle encapsulation by RBCs (Figure 3C and
Figure 4 bottom). The membrane wrapping around
l-MSNs led to an echinocytic (spiculated) shape transfor-
mation of RBCs and a reduction in the ratio of surface area
to volume.42 This inability tomaintain their normal surface
area and control their cell volume can ultimately lead
to the destruction of these cells,42 which explains the
observed high hemolytic activity of l-MSNs.
Two main processes are involved in the interaction
of MSN with the membrane of RBC: (1) binding of the
silanol-rich surface of MSNs with the phosphatidyl
choline-rich RBC membrane,30 and (2) bending of the
RBC membrane to adapt to the rigid surface of MSNs
(Scheme 1).43-47 The occurrence of the interaction
depends on whether the amount of energy released
from the binding of the MSNs with the RBC membrane
(Ei) is able to overcome the amount of free energy
required to bend the membrane and adapt to the
surface of MSNs (Eb). The former energy is associated
with the external surface area (i.e., accessible silanols)
of MSN,30 while the latter is proportional to the curva-
ture or inversely proportional to the square of the
radius (r) of the particle.43,44,47 The external surface
areas of s-MSNs and l-MSNs, calculated from the t plots
of their N2 adsorption isotherms,
48 were 81.6 and
155.4 m2 g-1, respectively. The relatively large external
surface area of l-MSN (40% of total surface area) in
comparison to that of s-MSN (8% of total surface area)
implies that l-MSN can have a larger binding energy (Ei)
available for pulling the membrane to the particle
surface. In addition, since surface curvature decreases
with particle size, the bending energy required to wrap
the large particles (Eb) is lower than the one needed to
wrap the smaller particles.43 This combination makes
membrane wrapping and engulfment of l-MSN thermo-
dynamically favorable. On the contrary, in order for the
RBC membranes to wrap around smaller s-MSNs, they
would have to attain a larger curvature (steeper angles
over smaller areas) than they need for wrapping around
the larger particles.43 This would require investing amuch
higher Eb compared to the small amount of Ei, which
thermodynamically prevents themembrane deformation
Figure 1. Scanningelectron (top) and transmission electron (bottom) images of (a,d) s-MSNand (b,e) l-MSN. (c) Hydrodynamic
size distributions of s-MSN (blue) and l-MSN (red) suspended in PBS (100 μg mL-1) measured by dynamic light scattering.
(f) X-ray diﬀraction patterns of s-MSN (blue) and l-MSN (red).
Figure 2. Hemolysis assay for s-MSN (green lines) and l-MSN
(red lines), using water as a positive control (blue lines)
and PBS as a negative control (dashed black lines). The
materials were suspended at 50 (a,c) and 100 μgmL-1 (b,d).
The mixtures were centrifuged to detect the presence
of hemoglobin in the supernatant visually (a,b) and by
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or engulfment of s-MSN by RBC and explains the lower
hemolytic activity of s-MSNs. Similar explanations on the
eﬀect of particle size on membrane wrapping have been
reported elsewhere.43,44 Hence, the interaction of MSNs
Figure 3. Scanning electron images of RBCs (5% hematocrit) incubated for 2 h at room temperature with (A) PBS as control,
(B) 100 μg mL-1 of s-MSN, and (C) 100 μg mL-1 of l-MSN. Images increase in magniﬁcation from left to right with features
highlighted with white squares or arrows. The nanoparticles attached on the cell surface are distinguished by the particle
shape and surface textural diﬀerence between the particles and RBCs. (Additional high-magniﬁcation images are shown in
Figure S2 in Supporting Information.)
Figure 4. Transmission electron images of RBCs (5% hematocrit) incubated for 2 h at room temperature with 100 μg mL-1
s-MSN (top) and l-MSN (bottom). Images increase in magniﬁcation from left to right. The presence of MSNs is conﬁrmed by
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with RBC membranes and the hemolytic activity depend
on not only particle size but also their external surface
area, as well.
Size- and Surface-Dependent Engulfment of MSNs by RBCs.
Though the in vitro endocytosis of MSN has been
systematically investigated with various mammalian
cell lines,4,11,17,34,36,49-52 little is known about the
uptake of nanoparticles by RBCs. This is partly because
the interactions between RBC and MSN are still poorly
understood. Before investigating the internalization of
MSNs by RBC, it is necessary to establish the concen-
tration at which the plasma membrane maintains its
integrity and RBCs retain normal biconcave shape. To
do so, the RBCswere incubatedwith l-MSNs at different
concentrations, and the hemolytic effects aswell as the
resulting cell morphologies were examined by UV-vis
spectroscopy (Figure S3 in Supporting Information)
and SEM (Figure S4). The hemolysis percentage of RBCs
increased from 1 to 11% as the concentration of l-MSN
increased from 20 to 100 μg mL-1, and growing
proportions of spiculated RBCs were observed with
increasing concentrations of l-MSN. As shown in Figure
S4, almost 90% of RBCs exhibited spiculated shape
with 100 μg mL-1 of l-MSN. The proportion of spicu-
lated RBCs decreased to 50% when 50 μg mL-1 of
l-MSN was used. Interestingly, only minor shape mod-
ifications (less than 10% spiculated cells) in RBCs were
observed after incubation with 20 μg mL-1 of l-MSN,
even if many particles were adsorbed to the mem-
branes or underwent internalization (Figure S4, left).
Therefore, the cellular uptake process was examined at
a concentration of 20 μg mL-1 of l-MSN (Figure 5). It
should be noted that the images in Figure 5 corre-
spond to different cells at different stages of nanopar-
ticle encapsulation. A plausible interpretation of our
observations is as follows. The particle interacts with an
initially flat cell membrane. Driven by a local reduction
in free energy (Scheme 1), the phospholipids in the
immediate neighborhood of the site of contact are
drawn to the surface of the particle, leading to mem-
brane wrapping and eventual encapsulation. Such
internalization is different from phagocytosis or endo-
cytosis because it appears to be driven by the balance
of two opposing forces rather than by an active uptake
of nutrients by the cell. It should be stressed that even if
almost no hemolysis or spiculation is observed at this
concentrationwe cannot yet exclude the potential side
effects of the internalization of l-MSN into RBC. Never-
theless, this preliminary study on MSN engulfment by
RBC is an important step toward establishing the
plausibility of using MSNs as tools for the treatment
of RBC-related diseases or intravascular drug delivery.
We are currently conducting more studies to under-
stand and control the internalization of MSNs and
the delivery of therapeutic agents into RBCs to be pub-
lished in subsequent manuscripts.
Surface Functionality Effects on RBC-MSN Interaction. The
results from the size- and surface-dependent inter-
actions of MSNs with RBCs have demonstrated a supe-
rior hemocompatibility of s-MSNs over l-MSNs. This
does not imply, however, that s-MSNs lack any inter-
action with the membranes of RBCs. While the inter-
actions of MSNs with the membranes of RBCs are
known to be dependent on the presence of silanol
groups on the surface of the particles,30,31 there is no
quantitative information on the magnitude of this
association. Given the interest of utilizing s-MSNs for
intravenous drug delivery, it is necessary to be able
to measure and control the degree of the above-
mentioned interactions and, thus, controlling the cir-
culation of the particles in the bloodstream.40,53
To study these interactions, s-MSNs were ﬁrst labeled
with ﬂuorescein isothiocyanate (FITC), which enabled
their tracking by ﬂow cytometry and confocal ﬂuores-
cence microscopy. FITC-s-MSNs were then functionalized
withdiﬀerent amounts of aminopropyl (AP), polyethylene
glycol (PEG), and carboxyl (CA) groups, as described in the
Methods section. These functionalized materials are re-
ferred as APx-FITC-s-MSN, PEGx-FITC-s-MSN, and CAx-FITC-
s-MSN, respectively, where the subscript x corresponds to
thenumberofmmol introducedpergramofmaterial. The
amount of functional groups (AP, PEG, andCA) grafted on
MSNs was quantiﬁed by TGA shown in the bottom of
Figure S5 of the Supporting Information and summarized
in Table S1. Thequantiﬁcationof nanoparticle attachment
to the membrane of RBCs was performed by ﬂow cyto-
metry. Diluted suspensions of RBCs (5  106 cells mL-1)
were mixed with equal volumes of nanoparticle suspen-
sions to reachaﬁnal concentrationof 10μgmL-1 ofMSNs
and incubated at room temperature for 2 h before ﬂow
cytometry analysis. As shown in Figure 6, the functiona-
lized nanoparticles exhibited lower aﬃnity to RBC than
FITC-s-MSNs; furthermore, the aﬃnity decreased with
increasing degree of functionality. This trend was ob-
served for each functionalized material, independent of
the surface charge. In particular, AP and PEG groups
(∼25% of RBC bound with AP1.5-FITC-s-MSN and ∼20%
with PEG1-FITC-s-MSN) showed a signiﬁcantly better
Scheme 1. Schematic illustration of the size- and surface-
dependent interaction of MSN and RBC membrane. MSN
with radius r can be wrapped around or engulfed by RBC
if the energy (Ei) released from the RBC-MSN interaction
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ability to reduce the MSN binding with RBC than CA
groups (∼65% of RBC bound with CA1.5-FITC-s-MSN). The
inhibitory eﬀect of PEG on the adsorption of MSN to RBC
was not surprising since PEGylation of nanoparticles is
generally used to block nonspeciﬁc binding of nanopar-
ticles to proteins.54 On the contrary, the reduction of MSN
binding to RBC due to aminopropyl group functionaliza-
tion was completely unexpected because amines are
well-known to facilitate adsorption of several biomole-
cules to the surface of nanoparticles and facilitate many
nanoparticle-cell interactions.34,55 The reduced bind-
ing of AP-FITC-s-MSN to RBC could be explained by the
electrostatic interaction between amino groups on the
surface of MSNs and surface silanols,56 which diminishes
the accessibility of silanol groups to the cell membrane.
The results obtained by ﬂow cytometrywere further
conﬁrmed by examination of the mixtures of the
derivatized MSNs with RBCs under confocal ﬂuores-
cence microscopy. For this purpose, RBCs were ﬁrst
labeled with PKH26 red ﬂuorescent dye (Sigma) and
incubated with FITC-labeled particles at the same con-
ditions as in the ﬂow cytometry experiment. FITC-l-MSNs,
FITC-s-MSNs, and CA1.5-FITC-s-MSNs (Figure 7a,b,e) were
easily observed associated to PKH26-labeled RBCs. Con-
versely, only a small proportion of AP1.5-FITC-s-MSNs
(Figure 7c) and PEG1-FITC-s-MSNs (Figure 7d) were found
colocalized with PKH26-RBCs, while most of the particles
were observed in the extracellular space. A series of
movies showing eachone of these combinations ofMSNs
and RBCs were prepared from micrographs taken at
diﬀerent z-positions by changing the focal plane every
0.5 μm; these movies can be found in the Supporting
Information. The diﬀerent aﬃnities of each MSN for the
RBCs were also conﬁrmed by the diﬀerent shifts of the
green ﬂuorescence intensities in the 2D dot plots from
ﬂow cytometry (Figure 7, bottom).
Effect of RBC-MSN Interaction on RBC Deformability. The
attachment of nanoparticles to the surface of red blood
cells has been suggested for extending the circulation
time and sustained release of therapeutic agents.40,53
Such attachment, however, could have an impact on
the properties of the membrane affecting the normal
function of RBCs. Surprisingly, this potential problem
has not been addressed for any nanoparticle-based
drug carrier, to the best of our knowledge. One of the
key properties of RBCs (6-8 μm in diameter) is their
Figure 5. Cellular uptake process (left to right) examined by transmission electron microscopy of RBCs (5% hematocrit)
incubated with 20 μg mL-1 l-MSN. Images increase in magniﬁcation from top to bottom, with features highlighted in white
arrows. These images (left to right) correspond to diﬀerent cells at diﬀerent stages of nanoparticle encapsulation.
Figure 6. Flow cytometry measurement of RBCs (5  106 cells mL-1) incubated with 10 μg mL-1 of (a) APx-FITC-s-MSN,




ZHAO ET AL. VOL. 5 ’ NO. 2 ’ 1366–1375 ’ 2011 1372
www.acsnano.org
ability to undergo deformation to traverse the capillaries
of the microvascular system (2-3 μm in diameter). This
remarkable deformability of RBCs is critical for effective
blood flow and depends strongly on the flexibility of the
cell membrane. This is the reason why it is important to
assess theeffects ofMSNattachmenton thedeformability
of RBCs.
To study the deformability of RBCs, we used a
literature reported method consisting of ﬁltering the
cells through polycarbonate membranes with straight
channels of 3 μm pore diameter (Nucleopore).41 This
technique is generally accepted as a relative indication
of RBC deformability.41,57-59 We measured the ﬁlter-
ability of fresh human RBCs (5% hematocrit) previ-
ously incubated with varying concentrations (10, 20,
50 μg mL-1) of MSN under a constant negative pres-
sure (-20 cm H2O). The time it took each RBC suspen-
sion to ﬂow through the membrane was recorded and
the deformability index (DI) was expressed as the
volume (mL) of red blood cells ﬁltered per minute. As
shown in Figure 8a, the deformability of RBC decreased
with increasing concentrations of all MSN materials.
The RBC deformability was severely impaired by l-MSN
at concentrations as low as 10 μg mL-1. This result is
not surprising given the strong aﬃnity and shape
altering eﬀects already described for l-MSN. As ex-
pected, the incorporation of AP and PEG groups
to the surface of s-MSN preserved the elasticity of
RBCs better than the nonfunctionalized s-MSN and
the CA-s-MSN, especially at the higher concentrations
(>20 μg mL-1). These results correlate well with the
observed eﬀects on the degree of RBC-MSN inter-
actions (Figure 8b). These observations suggest that
the attachment of MSNs to the surface of RBCs restricts
the ﬂexibility of the membrane and leads to impair-
ment in the deformability of RBCs. Conversely, the
attachment of functional groups to the surface ofMSNs
reduces the aﬃnity of the particles to themembrane of
RBC and allows the cells to preserve their deformability.
CONCLUSION
In this study, we investigated the interactions be-
tween MSNs of diﬀerent particle sizes and surface
properties and RBC membranes by using ﬂuorescence
and electronmicroscopies and cell biology techniques.
We compared the size- and surface-dependent hemo-
compatibility of two types of MSN materials (MCM-41
and SBA-15) and showed, for the ﬁrst time, how MSNs
are engulfed by RBCs. This size- and surface-dependent
process is the resultant of two opposing forces, namely,
the attractive interaction between MSNs and RBCs and
the bending of the cell membrane. These results
suggest that only small MCM-41-type MSN materials
(100-200 nm) may be considered as potentially safe
candidates for intravascular drug delivery. It must be
noted that, although RBCs are the dominant cells in
blood, the interactions of these nanoparticles with
other blood cells and components60,61 should also be
Figure 7. Confocalﬂuorescencemicrographs (top) anddot plots from theﬂowcytometry analyses (bottom)of PKH26-labeled
RBCs (5  106 cells mL-1) incubated with 10 μg mL-1 of (a,f) FITC-l-MSN, (b,g) FITC-s-MSN, (c,h) AP1.5-FITC-s-MSN, (d,i)
PEG1-FITC-s-MSN, and (e,j) CA1.5-FITC-s-MSN. The axes correspond to the intensity of red ﬂuorescence due to PKH26 labeling
(horizontal axis) and green ﬂuorescence due to the attachment of FITC-MSNs onto PKH26-RBCs (vertical axis). The plot was
gated to show PKH26-labeled RBCs in area Q4 and FITC ﬂuorescent PKH26-RBCs in area Q2. Individual channels for the
merged confocal images and enlarged dot plots with PKH26-RBC control are shown in Supporting Information Figure S7 and
Figure S8, respectively.
Figure 8. (a) Deformability index (DI) of RBCs incubated
with s-MSN (blue), AP1.5-s-MSN (green), PEG1-s-MSN (black),
CA1.5-s-MSN (purple), and l-MSN (red). (b) Flow cytometry
analyses of RBCs incubated with FITC-l-MSN (red), FITC-
s-MSN (blue), AP1.5-FITC-s-MSN (green), PEG1-FITC-s-MSN
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evaluated to ensure the safe use of these materials for
biomedical applications. In addition, we demonstrated
that the biocompatibility of these MSN materials with
RBCs strongly depends on their surface derivatization
tominimize their interactionwith redblood cells. Blocking
the surface silanols of the particles with organic groups
reduces their interactions with the membranes of RBCs.
Minimizing these interactions has a dramatic eﬀect on
preserving the deformability of RBCs, which is necessary
to ensure eﬀective blood circulation. These ﬁndings
suggest that it is possible to gain control over the inter-
actions ofMSNswith RBCmembranes in order to regulate
their circulationhalf-lives for various therapeuticpurposes,
while minimizing their toxicity by carefully choosing and
tuning their surface functionalities. As new MSN-based
drug delivery systems burgeon from many international
research groups, our results will provide a practical guide
to size and surface considerations when designing MSN-
based drug carriers for delivery, diagnostic, and therapeu-
tic applications.
METHODS
Synthesis of Mesoporous Silica Nanoparticles. s-MSNwas prepared
by our previously reported method.33 In brief, N-cetyltrimethyl-
ammonium bromide (CTAB, 1.00 g, 2.74 mmol) was dissolved in
480mL of nanopurewater, followed by the addition of 3.5mL of
sodium hydroxide aqueous solution (2.0 M), and the mixture
was heated to 80 C. Tetraethoxysilane (TEOS, 5.0 mL, 22.4
mmol) was added dropwise to the surfactant solution under
vigorous stirring. The reaction mixture was stirred at 80 C for
another 2 h. The resulting white solid was filtered, washed
thoroughly with water and methanol, and dried under high
vacuum at 80 C overnight. The fluorescent-labeled MSN (FITC-
s-MSN) was synthesized by reacting fluorescein isothiocyanate
(FITC, 15 mg, 38.5 μmol) with (3-aminopropyl)trimethoxysilane
(APTMS, 10 μL, 57.3 μmol) for 2 h in dimethyl sulfoxide (DMSO)
and adding the resulting product following the addition of TEOS
in the above synthesis. The unlabeled FITC was removed by
Soxhlet extraction with methanol. The amount of FITC labeled
on FITC-s-MSN was quantified to be 20-30 μmol g-1 by TGA.
The functionalization of s-MSN and FITC-s-MSN with aminopro-
pyl (AP), polyethylene glycol (PEG), and carboxylate (CA) groups
was performed by refluxing a suspension of the as-made
material (200 mg of s-MSN or FITC-s-MSN) with APTMS, 2-
[methoxy(polyethylenoxy)propyl]trimethoxysilane (PEG-silane),
and 3-(triethoxysilyl)propylsuccinic anhydride of various amount
(x mmol) in anhydrous toluene (50 mL) for 20 h, followed by
filtration andwashingwith toluene andmethanol, and dried under
high vacuum overnight. The succinic anhydride groups were
hydrolyzed by boiling the materials in water for 6 h and measured
by FTIR. The CTAB surfactant was removed by refluxing the
materials in0.37%HClmethanol, followedby filtrationandwashing
with abundant methanol and dried under high vacuum. The
amount of functional groups (AP, PEG, and CA) grafted on MSNs
was quantified by TGA shown in the bottom of Figure S5 and
summarized in Table S1.
l-MSN was prepared by a modiﬁed literature procedure.5
Pluronic P104 (courtesy of BASF, 7.0 g) was dissolved in a mix-
ture of water (164 g) and HCl (109 g, 4M) and stirred at 55 C for
1 h. Tetramethyl orthosilicate (10.64 g) was quickly added into
the solution at 55 C. After continuous stirring for 24 h, the
reaction mixture was moved to a Teﬂon-lined, high-pressure
autoclave for further hydrothermal treatment at 150 C for 24 h.
The product was isolated by ﬁltration, washed with copious
water andmethanol, and dried at 80 C in air. The Pluronic P104
surfactant was removed by calcination at 550 C for 6 h. The
l-MSN was ﬂuorescently labeled (FITC-l-MSN) by reacting FITC
(15 mg, 38.5 μmol) with APTMS (10 μL, 57.3 μmol) for 2 h in
dimethyl sulfoxide (DMSO) and adding the resulting product to
a suspension of l-MSN (1 g) in anhydrous toluene (100 mL) for
20 h, followed by ﬁltration and washing with toluene and
methanol. The unlabeled FITC was removed by Soxhlet extrac-
tion with methanol as the solvent. The amount of FITC labeled
on FITC-l-MSN was quantiﬁed to be around 30 μmol g-1.
The products were characterized by X-ray diﬀraction in a
Rigaku Ultima IV diﬀractometer, nitrogen sorption analysis in a
Micromeritics Tristar 3000 surface area, and porosity ana-
lyzer using Brunauer-Emmett-Teller (BET) equation to cal-
culate apparent surface area and pore volume and the
Barret-Joyner-Halenda (BJH) method to calculate pore size dis-
tribution, thermogravimetric analysis (TGA) in a TGA 2950 thermo-
gravimetric analyzer with a temperature ramp of 5 C/min in air,
dynamic light scattering size analyses of particle suspensions in a
Malvern NanoHT Zetasizer, scanning electronmicroscopy (SEM) of
samples coatedwith gold in a FEI Quanta 250 FEGmicroscope, and
transmission electron microscopy (TEM) of samples supported on
coppergrids in aTecnaiG2F20microscopeoperatedat200kV. FTIR
spectroscopy was performed using a Nicolet Nexus 470 (Madison,
EI), equipped with a cooled CT/A detector and an Ever-Glo source.
Isolation and Labeling of Red Blood Cells (RBCs). Ethylenediamine
tetraacetic acid (EDTA)-stabilized human blood samples were
freshly collected in the Occupational Medicine Office of Iowa
State University and Ames Laboratory. Whole blood was cen-
trifuged at 1600 rpm for 5 min, and the plasma, buffy coat, and
top layer of cells were decanted. The remaining packed RBCs
were washed five times with sterile isotonic PBS. For labeling
with PKH26 (red fluorescent cell linker kit, Sigma, USA), 100 μL of
packed RBCs was resuspended in 1 mL of diluent C and mixed
with 1 mL of diluent C containing 4 μM PKH26. Cells were
incubated for 5 min at room temperature in the dark. The
reaction was stopped by adding 1 mL of plasma (heat inacti-
vated for 1 h at 65 C beforehand) for 1 min and centrifuged at
1600 rpm for 5 min. The stained RBCs were washed five times
with PBS to remove free pKH26 dye.
Hemolysis Assay. After cell washing, 200 μL of packed RBCwas
diluted to 4 mL with PBS (5% hematocrit). The diluted RBC
suspension (0.2 mL) was then mixed with s-MSN and l-MSN
suspensions in PBS (0.8 mL) at various concentrations. PBS and
water (0.8 mL) were used instead of MSN suspensions as
negative and positive control, respectively. The mixture was
gently vortexed and incubated at room temperature for 2 h,
followed by centrifuge (1600 rpm, 5min), and the absorbance of
the supernatant at 541 nm was measured by UV-visible
spectrometry. The percent hemolysis of RBCs was calculated
using the following formula: percent hemolysis = ((sample
absorbance - negative control absorbance)/(positive control
absorbance - negative control absorbance))  100.
Scanning Electron Microscopy (SEM). The diluted RBC suspension
(5% hematocrit, 0.2 mL) was mixed with s-MSN and l-MSN
suspensions in PBS (0.8 mL) at various concentrations and
incubated at room temperature for 2 h. The samples were then
fixed by adding a 1% glutaraldehyde solution dropwise over
5 min and further incubated at 37 C for 1.5 h, followed by
postfixation with 1% osmium tetroxide in PBS for 1.5 h. Cells
were dehydrated in increasing concentrations of ethanol (50, 60
70, 80, 90, and 100%) for 15 min each. The cell suspensions
were dropped onto glass coverslips, dried, and coated with Au
before viewing under a FEI Quanta 250 FEG scanning electron
microscope.
Transmission Electron Microscopy (TEM). The samples were pre-
pared, fixed, and dehydrated as above and stained with 2%
uranyl acetate in 70% ethanol at room temperature overnight.
The cells were washed three times with acetone and embedded
in Epon. The embedded samples were sectioned in 60 nm thick
slices on a sliding ultramicrotome. Thin sections supported on
copper grids were examined in a Tecnai G2 F20 microscope
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Flow Cytometry. After cell washing, 200 μL of RBC suspension
at 5  106 cells mL-1 was mixed with 200 μL of FITC-MSN sus-
pensions in PBS at 20 μg mL-1 and incubated at room temper-
ature for 2 h before flow cytometry analysis in a BD FACSCanto
instrument.
Confocal Fluorescence Microscopy. PKH26-labeled RBC suspension
(200 μL) at 5 106 cells mL-1 was mixed with 200 μL of FITC-MSN
suspensions in PBS at 20 μg mL-1 and incubated at room tem-
perature for2h.Analiquotof samplewasmountedbetweenplastic
coverslips and imaged in a Leica SP5 X confocal system.
Deformability Assay. Packed RBCs (1.5 mL) were washed and
diluted to 30 mL with PBS (5% hematocrit). The diluted RBC
suspension (1mL) was thenmixedwithMSN suspensions in PBS
(4 mL) at various final concentrations of 10, 20, and 50 μg mL-1
with PBS as control. The mixture was gently vortexed and
incubated at room temperature for 2 h before filtering through
polycarbonate membrane with straight channels of 3 μm pore
diameter (Nucleopore, Fisher, USA) under a constant negative
pressure (-20 cm H2O). The time for 0.5 mL RBC suspension to
pass through the membrane was recorded, and the deform-
ability index (DI) was calculated as the volume of red blood cells
filteredperminute. Datawerepresentedasmeanvaluesof triplicate
experiments. Thepresentmethodandapparatus for RBC filterability
measurement have been described in detail elsewhere.41
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